Albendazole

Overview

Albendazole (e.g., Valbazen, Albenza) is a broad-spectrum benzimidazole anthelmintic widely used in food-producing animals for the control of internal parasites, including many nematodes, cestodes, and trematodes. Its antiparasitic activity is primarily related to disruption of parasite microtubule function through binding to beta-tubulin, which impairs cellular transport and energy metabolism, leading to parasite death.

For these reasons, albendazole should be considered contraindicated in dogs and cats. When parasite control is needed in small animal practice, safer benzimidazole alternatives (such as fenbendazole) or other appropriate anthelmintic classes should be selected instead

Why it is dangerous in small animals: albendazole has an affinity for rapidly dividing cells, so toxicity targets the bone marrow and intestinal epithelium. High doses have been associated with bone marrow toxicity (leukopenia, thrombocytopenia) in dogs and cats, which is the basis for the contraindication.

Indications

Albendazole has no approved or recommended indications in dogs or cats. In small animal practice, this drug is not considered an appropriate therapeutic option due to significant safety concerns and the availability of safer, well-established alternatives.

Although albendazole has been reported historically in extra-label use for certain parasitic conditions, current veterinary consensus discourages its use in dogs and cats.

Preferred Alternatives in Dogs & Cats

When treatment of internal parasites is required in dogs or cats, the following agents are commonly preferred due to established safety and efficacy profiles:

• Fenbendazole – Broad-spectrum benzimidazole with a significantly wider safety margin
• Milbemycin oxime – Effective against several gastrointestinal and cardiopulmonary parasites
• Praziquantel – Preferred agent for cestode infections when indicated
• Moxidectin – Used in combination products for parasite control

Selection of antiparasitic therapy should be based on species-specific safety data, parasite identification, and current clinical guidelines.

Dosage (Reference)

There are no approved, recommended, or safe dosage regimens for albendazole in dogs or cats. Numerical dosing guidelines are intentionally not provided due to the narrow safety margin and the risk of serious, potentially irreversible toxicity.

Reports of historical extra-label dosing in small animals have been associated with adverse hematologic outcomes, including neutropenia and aplastic anemia. As such, dose adjustment or extrapolation from other species is considered unsafe.

Dosing Approach in Clinical Practice

Rather than attempting to determine a dose of albendazole, clinicians should select alternative antiparasitic agents with established dosing protocols for dogs and cats.

• Use drugs with species-specific labeling or well-supported extra-label data
• Avoid extrapolation of doses from food-producing animals
• Prioritize agents with predictable pharmacokinetics and wide safety margins

Warnings & Precautions

Albendazole carries a high risk of serious adverse effects in dogs and cats, particularly affecting rapidly dividing tissues.

• Hematologic toxicity: Hematologic toxicity: Albendazole can suppress bone marrow activity, leading to neutropenia, pancytopenia, and increased susceptibility to infections.
• Delayed onset of toxicity: Clinical signs and laboratory abnormalities may develop days to weeks after exposure, complicating early detection.
• Hepatic metabolism: Albendazole is extensively metabolized by the liver. Impaired hepatic function may alter drug handling and increase systemic exposure.
• Pregnancy risk: Albendazole has embryotoxic and teratogenic potential. It is contraindicated during the first trimester of pregnancy. accidental exposure may increase the risk of fetal loss or developmental abnormalities.
• Prolonged exposure: Prolonged exposure: Repeated or extended administration markedly increases the risk of cumulative toxicity. adverse effects are more likely when albendazole is given for longer than 5 days – avoid high doses and prolonged courses.
• Other species: Pigeons and doves are susceptible to albendazole toxicity (intestinal crypt epithelial necrosis and bone marrow hypoplasia). Toxicosis has also been reported in rabbits, often at higher-than-recommended dosages – use with caution in exotic and avian patients.

Drug Interactions

Specific interaction data for albendazole in dogs and cats are limited. However, certain drug combinations may increase systemic exposure or potentiate toxic effects. Given the narrow safety margin, concurrent drug use may significantly increase clinical risk.

• Cytochrome P450 inhibitors (e.g., cimetidine): Cytochrome P450 inhibitors (e.g., cimetidine): May reduce hepatic metabolism of albendazole, increasing plasma concentrations and toxicity risk.
• Corticosteroids: Corticosteroids: May increase systemic exposure to albendazole and its active metabolites, potentially exacerbating adverse effects.
• Other documented interactions: Myelotoxic drugs: Concurrent use with bone marrow-suppressive agents may compound hematologic toxicity. 

Potential drug interactions are best avoided by preventing albendazole exposure in dogs and cats altogether.

Key Notes

• Anorexia and reduced oral intake
• Weight loss
• Severity of adverse effects appears to increase with repeated or prolonged administration.
• Monitor CBC in animals experiencing signs suspicious of adverse effects
• Albendazole exposure in dogs and cats is associated with a high risk of serious hematologic toxicity.

Adverse Effects

: Ivermectin – co-administration decreased albendazole sulfoxide (active metabolite) AUC and increased ivermectin AUC in lambs. Praziquantel – may increase albendazole serum concentrations. Theophylline derivatives (aminophylline, theophylline) – albendazole may decrease theophylline concentrations; monitor.

Dogs

• Potential drug interactions are best avoided by preventing albendazole exposure in dogs and cats altogether.
• In dogs and cats, albendazole exposure has been associated with serious and sometimes life-threatening adverse effects. Toxicity is most commonly hematologic in nature but may involve multiple systems. Severity may increase with repeated or prolonged exposure.
• Bone marrow suppression
• Neutropenia and pancytopenia
• Aplastic anemia

Cats

• Anorexia and weight loss
• Lethargy and generalized weakness
• Increased susceptibility to secondary infections
• Severe bone marrow suppression
• Neutropenia and aplastic anemia

Lethargy and depression